FDA Permits Marketing of First Brain Wave Test to Help Assess Children and Teens for ADHD

On July 15, 2013, The U.S. Food and Drug Administration issued a press release announcing its decision to allow the marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old.
The complete press release may be found at:

Access Board Working Group on Accessible Prescription Drug Container Labels

The Access Board  has lead the effort to develop guidance on making prescription drug labels accessible to people with vision impairments.

The Food and Drug Administration Safety and Innovation Act of 2012 includes measures to promote drug safety and to improve FDA procedures for reviewing new medicines and medical devices. Continue reading “Access Board Working Group on Accessible Prescription Drug Container Labels”